EMA Authorised: Saxenda (liraglutide) — Novo Nordisk A/S

View source ↗

Summary

EMA authorised Saxenda (liraglutide) for obesity and overweight, with Novo Nordisk A/S as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• SAXENDA (liraglutide)

Snippet

Status: Authorised. Therapeutic area: Obesity;Overweight. MAH: Novo Nordisk A/S. Decision date: 25/06/2025